Please assess the completion status of the following clinical trial:

Trial Title: Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically proven diagnosis of CD20-positive marginal zone B-cell lymphoma of MALT type arisen at any extranodal site (WHO classification)~2. Any stage (Ann Arbor I-IV)~3. The novo disease en any extranodal site. For primary gastric or cutaneous lymphoma, local/specific previous treatment is accepted, just following the below criteria:~   1. Cutaneous lymphoma: recurrent lymphoma after local therapy~  2. Gastric lymphoma:~   b1. H. pylori-negative cases, either de novo (non pre-treated) or at relapse following local therapy (i.e., surgery, radiotherapy or antibiotics).~   b2. H. pylori-positive cases at diagnosis, who failed antibiotic therapy, including patients with: clinical (endoscopic) and histological evidence of disease progression at any time post H. pylori eradication; stable disease with persistent lymphoma at 1 year post H. pylori eradication; relapse (without H. pylori re-infection), after a remission; patients who failed either first line antibiotics or further local treatment (surgery or radiotherapy)~4. No evidence of histologic transformation to a high grade lymphoma~5. Measurable or evaluable disease~6. Age \>18 and \<85~7. ECOG performance status 0-2~8. Life expectancy of at least 1 year~9. Written informed consent given according to national/local regulations~Exclusion Criteria:~1. Prior chemotherapy or prior immunotherapy with any anti-CD20 monoclonal antibody~2. Prior radiotherapy in the last 6 weeks~3. Corticosteroids during the last 28 days, unless prednisone chronically administered at a dose \<20 mg/day for indications other than lymphoma or lymphoma-related symptoms~4. Major impairment of renal function (serum creatinine \> 2,5 x upper normal) or liver function (ASAT/ALAT \<2,5 x upper normal, total bilirubin \<2,5x upper normal), unless due to lymphoma involvement.~5. Impairment of bone marrow function (WBC \<3.0x109/L, ANC \<1.5x109/L, PLT \<100x109/L), unless due to lymphoma involvement~6. Evidence of clinically significant cardiac, neurological or metabolic disease, unless due to lymphoma involvement~7. Evidence of symptomatic central nervous system (CNS) disease~8. Active HBV and/or HCV infection~9. Known HIV infection~10. Prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer~11. Any psychiatric disease potentially hampering compliance with the study protocol and follow-up schedule~12. Potential to attend regular visits to the hospital, on an outpatient regimen~13. Hypersensibility to any compound of the study medication.~14. Non appropriate contraceptive method in women of childbearing potential or men~15. Treatment with any drug under research within 30 days previous to start the study medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab and Bendamustine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete